Latest:
Dr Abughanimeh on the Evolution of Targeted Therapy in EGFR+ NSCLC
Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.
Authors
Shahzad Raza, MD
Latest:
Prevalence of Eye Toxicities in Patients With Cancer Is Much Higher Than Previously Known
In the real-world setting, cases of ocular adverse effects have emerged with greater frequency both in new and established therapies than has been previously observed in many clinical trials.
Marco Davila, MD, PhD
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Latest:
Dr Davila on the Future Use of Biomarkers to Predict CAR T-Cell Therapy Resistance in LBCL
Marco Davila, MD, PhD, discusses how a study of tumor drivers of CAR T-cell therapy resistance in LBCL may promote future biomarker investigations.
Young Son, PGY3
Latest:
Dr Son on Urinary and Bowel Anastomotic Leak in Bladder Cancer
Young Son, PGY3, discusses the future implications of findings from a study investigating the association between neoadjuvant chemotherapy and increased urinary and bowel anastomosis failure in patients with bladder cancer who are undergoing radical cystectomy.
Richard L. Martin III, MD, MPH
Latest:
A Challenge to Medical Oncology Training Programs: Promote Equity in Training
In her 2020 American Society of Clinical Oncology presidential address, “Equity: Every patient. Every day. Everywhere,” Lori J. Pierce, MD, challenges medical oncology to imagine a future when equity is considered a humanistic standard of oncology practice.
Michael J. Fallon, MD
Latest:
Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma
Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.
Sanam Loghavi, MD
Latest:
Dr Loghavi on the Expansion of Genetically-Defined Subtypes in AML
Sanam Loghavi, MD, discusses the expansion of genetically-defined categories of acute myeloid leukemia in the World Health Organization classification, and how this affects the diagnosis of patients in this space.